High-throughput quantitation of serological dimethylarginines by LC/MS/MS: Potential cardiovascular biomarkers for rheumatoid arthritis
Qianyang Huang,Ying Liu,Yuna Cheng,Fujian Jia,Chunchao Pu,Qinghua Yan,Zhaoyu Chang,Ping Liao,Dandan Ma,Lei Xu,Hua Zhang,Yuanzhi Lu,Xin Liu,Kang Liu
DOI: https://doi.org/10.1016/j.jpba.2023.115336
IF: 3.571
2023-03-13
Journal of Pharmaceutical and Biomedical Analysis
Abstract:Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by systemic inflammation of the joints and extra-articular tissues. The incidence of cardiovascular disease (CVD) remains the main cause of morbidity and mortality in patients with RA. Despite the development of new therapeutics targeting the articular manifestations, the relief of the cardiovascular burden is still an unmet medical need during the management of RA. So, the early prognosis of RA-associated CVD plays a crucial role in improving the clinical outcomes of RA patients. Recently, circulating dimethylarginines have gained attention as potential biomarkers for CVDs. Here, we present the development and validation of a high-throughput liquid chromatography-tandem mass spectrometric (LC/MS/MS) method for simultaneous quantification of creatinine, arginine, and dimethylarginines in human serum within 2 mins by isotope dilution mass spectrometry. This method employed a protein precipitation method for rapid sample preparation, trichloroacetic acid (TCA)-based ion pairing chromatography for fast analyte separation, and multiple reaction monitoring (MRM) with stable isotope-labeled internal standards (ISs) for simultaneous quantitation. To assure the quality, our method was validated against the FDA guidelines for lower limit of quantitation (0.2 μM), linearity (square of coefficient correlation>0.99), precision (intra-&inter-assay imprecision<10%), accuracy (intra-&inter-assay inaccuracy<10%), sample preparation recovery (recovery ≥ 90%), stability (instability<10%), matrix effect (signal suppression<55%), and carryover (<0.01%). Afterward, we applied the validated method to a retrospective cross-sectional study. We aimed to evaluate the utility of serological dimethylarginines as potential cardiovascular biomarkers in the development of RA-associated CVD. Our results revealed that the serological ratio of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), an indicator of physiological arginine methylation status, was significantly elevated in patients with RA. This finding might provide value in detecting CVD to improve clinical outcomes in RA management.
pharmacology & pharmacy,chemistry, analytical